Design of the REVEAL registry for US patients with pulmonary arterial hypertension

Mayo Clinic Proceedings

Volumn 83, Issue 8, 2008, Pages 923-931

  McGoon, Michael D ^a   Krichman, Abby ^b   Farber, Harrison W ^c   Barst, Robyn J ^d   Raskob, Gary E ^e   Liou, Theodore G ^f   Miller, Dave P ^g   Feldkircher, Kathy ^h   Giles, Scott ^h  

^a MAYO CLINIC   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d Columbia University College of Physicians and Surgeons ^*  (United States)

^e UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

^f UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^g ICON CLINICAL RESEARCH   (United States)

^h Actelion Pharmaceuticals US Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANOREXIGENIC AGENT; ANTICOAGULANT AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIGOXIN; DIURETIC AGENT;

CARDIOPULMONARY EXERCISE TEST; DISEASE REGISTRY; FUNCTIONAL STATUS; HOSPITALIZATION; HUMAN; LUNG ARTERY PRESSURE; LUNG FUNCTION TEST; MEDICAL INFORMATION; MORTALITY; OUTCOME ASSESSMENT; PULMONARY HYPERTENSION; REVIEW; SURVIVAL; UNITED STATES; WALKING; WORLD HEALTH ORGANIZATION;

EID: 49249111028     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/83.8.923     Document Type: Article

References (15)

1. D'Alonzo GE, Barst RJ, Ayres SM, et al. Survival in patients with primary pulmonary hypertension: results from a national prospective registry. Ann Intern Med. 1991;115(5):343-349.
2. Rich S, Dantzker DR, Ayres SM, et al. Primary pulmonary hypertension: a national prospective study. Ann Intern Med. 1987;107(2):216-223.
3. Humbert M, Sitbon O, Chaouat A, et al. Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med. 2006 May 1;173(9):1023-1030. Epub 2006 Feb 2.
4. Jing ZC, Xu XQ, Han ZY, et al. Registry and survival study in Chinese patients with idiopathic and familial pulmonary arterial hypertension. Chest. 2007 Aug;132(2):373-379. Epub 2007 Mar 30.
5. Rich S, Rubin L, Walker AM, Schneeweiss S, Abenhaim L. Anorexigens and pulmonary hypertension in the United States: results from the surveillance of North American pulmonary hypertension. Chest. 2000;117(3):870-874.
6. Walker AM, Langleben D, Korelitz JJ, et al. Temporal trends and drug exposures in pulmonary hypertension: an American experience. Am Heart J. 2006;152(3):521-526.
7. Simonneau G, Galie N, Rubin LJ, et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2004;43(12)(suppl S):5S-12S.
8. Cox DR. Regression models and life-tables. J R Statist Soc B. 1972;34:187-220.
9. Cox DR, Oakes D. Analysis of Survival Data. 1st ed. London, England: Chapman and Hall; 1984.
10. Gross ST, Lai TL. Nonparametric estimation and regression analysis with left-truncated and right-censored data. J Am Stat Assoc. 1996;91(435):1166-1180.
11. Rubin DB. Estimating causal effects from large data sets using propensity scores. Ann Intern Med. 1997;127(8 pt 2):757-763.
12. Rubin DB. The design versus the analysis of observational studies for causal effects: parallels with the design of randomized trials. Stat Med. 2007;26(1):20-36.
13. Newgard CD, Hedges JR, Arthur M, Mullins RJ. Advanced statistics: the propensity score - a method for estimating treatment effect in observational research. Acad Emerg Med. 2004;11(9):953-961.
14. Hullsiek KH, Louis TA. Propensity score modeling strategies for the causal analysis of observational data. Biostatistics. 2002;3(2):179-193.
15. Stricker H, Domenighetti G, Popov W, et al, Swiss Group for Severe Pulmonary Hypertension. Severe pulmonary hypertension: data from the Swiss Registry. Swiss Med Wkly. 2001;131(23-24):346-350.